Topoisomerase Inhibitors: Mechanisms and Classes

Topoisomerase inhibitors are antineoplastic and antimicrobial agents that act on the topoisomerase enzymes responsible for managing the over- and under-winding (supercoiling) and entanglement of DNA. By interfering with these enzymes, the drugs convert routine DNA processing into lethal DNA damage in dividing cells.

Definition

Topoisomerase inhibitors are drugs that block the catalytic cycle of DNA topoisomerases — either by stabilising the transient enzyme-DNA covalent intermediate so it becomes a DNA break (poisons) or by preventing the enzyme from completing its reaction (catalytic inhibitors).

Scope

This topic covers what topoisomerase enzymes do, the central distinction between topoisomerase I and topoisomerase II, and the mechanistic split between poisons (which trap the enzyme on DNA) and catalytic inhibitors (which block enzyme turnover without trapping). It is a mechanism-and-classes reference, not a clinical prescribing guide.

Core questions

• What topological problems do topoisomerases solve during replication and transcription?
• How does a topoisomerase poison differ mechanistically from a catalytic inhibitor?
• Why does trapping the cleavage complex produce cell death?
• What distinguishes type I from type II topoisomerases as drug targets?

Key concepts

• DNA supercoiling and topology
• Type I topoisomerase (single-strand break)
• Type II topoisomerase (double-strand break, ATP-dependent)
• Cleavage complex
• Topoisomerase poison
• Catalytic (non-poison) inhibitor
• Replication/transcription collision with trapped complex

Key theories

Interfacial poisoning (cleavage-complex stabilisation)

Many topoisomerase inhibitors act not by blocking the active site but by wedging into the enzyme-DNA interface of the transient cleavage complex, preventing religation of the cut DNA; the persistent protein-linked break, encountered by replication or transcription, becomes the lethal lesion.

Mechanisms

Topoisomerases relieve torsional stress and disentangle DNA by transiently cutting one strand (type I) or both strands (type II) and passing DNA through the break before resealing it (Wang, 2002). During this cycle the enzyme is briefly bound to DNA through a covalent intermediate. Poisons such as camptothecins (acting on topoisomerase I) and many anthracyclines and epipodophyllotoxins (acting on topoisomerase II) stabilise this intermediate, the cleavage complex, so the cut is not resealed; when a replication fork or transcription machinery collides with the trapped complex, the result is a DNA break that activates damage responses and cell death (Pommier, 2006; Nitiss, 2009). Catalytic inhibitors, by contrast, interfere with other steps of the cycle (such as ATP binding for type II enzymes) and suppress enzyme activity without generating trapped breaks (Nitiss, 2009).

Clinical relevance

Topoisomerase inhibitors are widely used cytotoxic anticancer drugs, and the poison-versus-catalytic-inhibitor distinction helps explain their different activity and toxicity profiles. This entry is a mechanistic reference describing how the class works; it is not a source of dosing or individualised therapy.

Evidence & guidelines

The mechanistic account here is drawn from authoritative molecular and pharmacological reviews of topoisomerase biology and targeting (Wang, 2002; Pommier, 2006; Nitiss, 2009). Clinical indications for specific agents follow oncology guidelines addressed at the level of individual drugs rather than in this mechanism topic.

History

The recognition that topoisomerases are essential, druggable enzymes followed James Wang's characterisation of their cellular roles, and the later demonstration that agents like camptothecin act by trapping the enzyme on DNA reframed cytotoxic activity as 'poisoning' rather than simple inhibition (Wang, 2002; Pommier, 2006).

Key figures

• James C. Wang
• Yves Pommier
• John L. Nitiss

Seminal works

• pommier-2006
• nitiss-2009
• wang-2002

Frequently asked questions

What is the difference between a topoisomerase poison and a catalytic inhibitor?

A poison stabilises the enzyme-DNA cleavage complex so the DNA break is not resealed, turning the enzyme into a source of DNA damage; a catalytic inhibitor blocks the enzyme's activity without trapping it on DNA, so it suppresses function without directly generating breaks.

Why are topoisomerase I and II treated as separate drug targets?

Type I enzymes cut a single DNA strand and are ATP-independent, while type II enzymes cut both strands and use ATP; their different reaction mechanisms mean distinct drug classes target each, with different effects on the cell.